Scalper1 News
Aspiring specialty-drug giant Endo International (ENDP) agreed to buy major generic drugmaker Par Pharmaceutical Holdings for $8.05 billion Monday, a deal Endo says will make it one of the top five generic-drug makers in the world. Investors were a bit nervous, however, and Endo was down 2% in early trading in the stock market today. Endo agreed to shell out $6.5 million in cash and 18 million of its own shares to acquire Par from TPG Capital, the Scalper1 News
Scalper1 News